Literature DB >> 17005666

Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.

Andres F Mejia1, Timothy D Culp, Nancy M Cladel, Karla K Balogh, Lynn R Budgeon, Christopher B Buck, Neil D Christensen.   

Abstract

A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17005666      PMCID： PMC1676303          DOI： 10.1128/JVI.01583-06

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  16 in total

1.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Authors:  R Kirnbauer; L M Chandrachud; B W O'Neil; E R Wagner; G J Grindlay; A Armstrong; G M McGarvie; J T Schiller; D R Lowy; M S Campo
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Authors:  Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

4.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

5.  Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition.

Authors:  R B Roden; N L Hubbert; R Kirnbauer; N D Christensen; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  A controlled trial of a human papillomavirus type 16 vaccine.

Authors:  Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

7.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Efficient intracellular assembly of papillomaviral vectors.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321
View more
  20 in total

1.  A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.

Authors:  Hyunwook Lee; Sarah A Brendle; Stephanie M Bywaters; Jian Guan; Robert E Ashley; Joshua D Yoder; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Hyunwook Lee; Robert E Ashley; Alexander M Makhov; James F Conway; Neil D Christensen; Susan Hafenstein
Journal:  Virology       Date:  2015-05-19       Impact factor: 3.616

3.  The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans-Golgi network.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lydia Hilbig; Martin Sapp
Journal:  Virology       Date:  2014-05-08       Impact factor: 3.616

Review 4.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

5.  Antibody detection in tear samples as a surrogate to monitor host immunity against papillomavirus infections in vaccinated and naturally infected hosts.

Authors:  Jiafen Hu; Sarah Brendle; Karla Balogh; Stephanie Bywaters; Neil Christensen
Journal:  J Gen Virol       Date:  2014-06-05       Impact factor: 3.891

6.  Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Authors:  Kirill Kalnin; Timothy Tibbitts; Yanhua Yan; Svetlana Stegalkina; Lihua Shen; Victor Costa; Robert Sabharwal; Stephen F Anderson; Patricia M Day; Neil Christensen; John T Schiller; Subhashini Jagu; Richard B S Roden; Jeffrey Almond; Harold Kleanthous
Journal:  Vaccine       Date:  2014-04-26       Impact factor: 3.641

7.  Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Authors:  Subhashini Jagu; Balusubramanyam Karanam; Joshua W Wang; Hatem Zayed; Margit Weghofer; Sarah A Brendle; Karla K Balogh; Kerstin Pino Tossi; Richard B S Roden; Neil D Christensen
Journal:  Vaccine       Date:  2015-09-15       Impact factor: 3.641

8.  A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

Authors:  Ratish Gambhira; Balasubramanyam Karanam; Subhashini Jagu; Jeffrey N Roberts; Christopher B Buck; Ioannis Bossis; Hannah Alphs; Timothy Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

9.  The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy.

Authors:  Jian Guan; Stephanie M Bywaters; Sarah A Brendle; Hyunwook Lee; Robert E Ashley; Neil D Christensen; Susan Hafenstein
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

10.  Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.

Authors:  Alessandra Handisurya; Patricia M Day; Cynthia D Thompson; Christopher B Buck; Kihyuck Kwak; Richard B S Roden; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2012-09-15       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.